EBS — Emergent BioSolutions Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1367644 ·
Last close
$9.13
Market Cap
$471.07M
52W High
$9.66
52W Low
$7.53
ADV30
685,046
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 149,700,000 | 77,700,000 | 10,500,000 | 6,800,000 | 1,320,400,000 | 160,300,000 | 797,300,000 |
| Dec 2025 | 143,800,000 | 58,900,000 | -15,700,000 | -54,600,000 | 1,318,600,000 | 205,400,000 | 796,000,000 |
| Sep 2025 | 222,000,000 | 136,100,000 | 76,500,000 | 51,200,000 | 1,461,000,000 | 245,500,000 | 878,500,000 |
| Jun 2025 | 130,300,000 | 63,400,000 | 1,600,000 | -12,000,000 | 1,417,100,000 | 267,300,000 | 880,900,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$148,000,000
Investing CF
$7,500,000
Financing CF
$-147,600,000
CapEx
$-12,600,000
Dividends Paid
—
Buybacks
$-33,900,000
EPS Diluted TTM
$-0.28
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-153,000,000
Inventory
$327,600,000
Receivables
$121,600,000
ST Investments
—
EBIT TTM
$59,100,000
Pretax Income TTM
$3,500,000
Interest Exp TTM
$55,600,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$676,800,000
EBITDA
$166,700,000
Free Cash Flow
$256,212,496
Enterprise Value
$860,288,704
Total Cash
$160,300,000
Total Debt
$584,600,000
Shares Out
51,596,296
Trailing EPS
$-0.19
Book Value
$10.10
ROE
-1.6%
ROA
3.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 705,200,000 | 112,300,000 | 52,600,000 | 1,318,600,000 | 796,000,000 | — | 170,600,000 |
| Dec 2024 | 1,013,600,000 | -81,500,000 | -190,600,000 | 1,389,700,000 | 906,900,000 | — | 58,700,000 |
| Dec 2023 | 1,023,000,000 | -201,500,000 | -760,500,000 | 1,823,200,000 | 1,173,900,000 | — | -206,300,000 |
| Dec 2022 | 1,076,100,000 | -163,300,000 | -211,600,000 | 3,166,300,000 | 1,778,600,000 | — | -34,100,000 |
TTM Snapshot
Revenues TTM
$1,046,900,000
NetIncome TTM
$-292,100,000
OpCashFlow TTM
$0
Assets (Latest)
$1,389,700,000
Forward EPS
$2.99
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STTK | Shattuck Labs, Inc. | $468.52M | $6.11 | — |
| CATX | Perspective Therapeutics, Inc. | $474.43M | $4.16 | — |
| KMDA | KAMADA LTD | $458.60M | $7.95 | — |
| CYDY | CytoDyn Inc. | $457.62M | $0.34 | — |
| OVID | Ovid Therapeutics Inc. | $457.27M | $2.45 | — |
News headlines (Yahoo Finance, 1h cache)
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
2026-05-20 20:43 · Yahoo
Emergent BioSolutions to Participate in Upcoming Investor Conferences
2026-05-20 11:30 · Yahoo
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
2026-05-18 12:59 · Yahoo
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved
2026-05-02 14:29 · Yahoo
Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary
2026-05-01 12:30 · Yahoo
Emergent Biosolutions Q1 Earnings Call Highlights
2026-05-01 11:18 · Yahoo
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic ...
2026-05-01 07:19 · Yahoo
Emergent BioSolutions Reports First Quarter 2026 Financial Results
2026-04-30 20:30 · Yahoo
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
2026-04-30 11:55 · Yahoo
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
2026-04-29 11:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.